A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

NCT01610336 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: INC280
DRUG: Gefitinib

Sponsor

Novartis Pharmaceuticals